RecruitingNot ApplicableNCT06781515
Assessment of Disease Burden in Hairy Cell Leukemia
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
45 participants
Start Date
Jan 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Drug-free, single-center, prospective observational pilot study in hairy Cell Leukemia patients
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is looking at the burden of disease in people with hairy cell leukemia — a rare, slow-growing blood cancer — at different stages: newly diagnosed, in relapse, or in remission. Researchers want to better understand treatment needs and long-term outcomes.
**You may be eligible if...**
- You are 18 or older
- You have a confirmed diagnosis of hairy cell leukemia
- You are newly diagnosed and about to start treatment, OR in relapse needing further therapy, OR in remission for at least 5 years
**You may NOT be eligible if...**
- You have a second active cancer at the same time
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERPeripheral and BM blood sample
Peripheral and BM blood samples will be analyzed with the ddPCR method
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06781515
Related Trials
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
NCT069651144 locations
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
NCT0656136010 locations
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
NCT048153561 location
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
NCT043223831 location
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
NCT043241121 location